CAR NK cell therapy is a form of immunotherapy.
NK cells are an important form of immunotherapy.
NK cells are an important component of the innate immune system
NK cells are engineered ex vivo to express a CAR enabling the cells to recognize and eliminate cancer cells more effectively.
Unlike CART cells, NK cells in the allogeneic setting do not cause graft versus host disease, so they can safely be administered from a healthy donor to a patient.
CAR T-cell products are all autologous and manufactured as a patient specific product from patient’s own cells, adding complexity and cost.
CART cell therapy also carries risk of toxicity that are not commonly observed with NK cell therapy, namely, cytokinine release syndrome, and immune effector cell associated neurotoxicity (ICANS).
CAR NK cell therapy can potentially be used as an off the shelf product.
Cells from one healthy donor can be used to manufacture dozens or even hundreds of doses that can be frozen and available for use as needed.
CAR NK cells are usually administered intravenously, but can also be administered locoregionally to improve delivery.
This approach combines the innate cytotoxic capabilities of NK cells with the precision of antigen-directed targeting.[1][2]
CAR-NK cells function through dual mechanisms of tumor recognition.
They retain their natural ability to identify and eliminate malignant cells through innate NK cell receptors, while the engineered CAR provides MHC-independent recognition of specific tumor antigens.
The CAR construct typically consists of an extracellular antigen-recognition domain (often derived from antibodies), transmembrane domain, and intracellular signaling domains that activate the NK cell upon antigen binding.
CAR-NK cells offer several advantages over CAR-T cell therapy, including a significantly improved safety profile with minimal or no cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GvHD).
This favorable safety profile enables the use of allogeneic NK cells as off-the-shelf products without requiring HLA matching, addressing the manufacturing complexity and cost limitations of autologous CAR-T therapies.
NK cells for CAR engineering can be derived from multiple sources:
Peripheral blood (autologous or allogeneic)
Umbilical cord blood
Induced pluripotent stem cells (iPSCs)
NK cell lines
Hematopoietic stem cells
CD19-directed CAR-NK cells derived from cord blood showed complete responses in 8 of 11 patients with relapsed/refractory CD19-positive lymphoid malignancies, with no development of CRS, neurotoxicity, or GvHD.
Current challenges include optimizing CAR-NK cell persistence in vivo, enhancing tumor infiltration in solid tumors, and overcoming the immunosuppressive tumor microenvironment.
Strategies to address these limitations include incorporating cytokine support (such as IL-15), combining CAR-NK therapy with checkpoint inhibitors or other immunotherapies, and using advanced gene editing techniques to enhance NK cell function.